Sarepta Therapeutics, Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
Sarepta is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, gene therapy and other genetic medicines for rare diseases, primarily Duchenne muscular dystrophy. The filing covers the three and six months ended June 30, 2023, and was filed August 2, 2023. The company had four FDA accelerated-approved products: EXONDYS 51, VYONDYS 53, AMONDYS 45 and, newly approved on June 22, 2023, ELEVIDYS. No ELEVIDYS product revenue was recorded during the quarter or first half.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $261.2 million | $233.5 million | $514.7 million | $444.3 million |
| Product revenue | $239.0 million | $211.2 million | $470.5 million | $400.1 million |
| Collaboration revenue | $22.3 million | $22.3 million | $44.3 million | $44.3 million |
| Operating loss | $(133.5) million | $(211.1) million | $(271.6) million | $(298.0) million |
| Net loss | $(23.9) million | $(231.5) million | $(540.7) million | $(336.5) million |
| Net loss per share | $(0.27) | $(2.65) | $(6.11) | $(3.85) |
| Cash used in operating activities | Not separately provided | Not separately provided | $(331.6) million | $(168.0) million |
Product revenue increased 13% in Q2 and 18% for the first half, driven by demand for the PMO products. Q2 product revenue comprised EXONDYS 51 of $134.7 million, AMONDYS 45 of $71.7 million and VYONDYS 53 of $32.6 million. The company reported an approximate gross margin of 87% for both Q2 and the first half, based on reported revenue less cost of sales and amortization of in-licensed rights. Operating margins were approximately negative 51% in Q2 and negative 53% for the first half.
At June 30, 2023, cash and cash equivalents were $851.9 million, short-term investments were $1,008.8 million and restricted cash was $19.0 million, for total cash, cash equivalents, restricted cash and investments of approximately $1.88 billion. Management believes these resources are sufficient to fund the current operating plan for at least the next twelve months.
Long-term debt carrying value was $1.24 billion, consisting of approximately $105.8 million principal of 2024 Notes and $1.15 billion principal of 2027 Notes. Debt principal maturities are $105.8 million in 2024 and $1.15 billion in 2027. Working capital was $1.97 billion at June 30, 2023.
Material changes versus the prior comparable period
- Revenue increased $27.8 million, or 12%, in Q2 and $70.4 million, or 16%, in the first half.
- Q2 operating loss improved by $77.6 million, primarily because of lower manufacturing costs and lower stock-based compensation. First-half operating loss improved by $26.4 million.
- Q2 net loss improved by $207.5 million, aided by a $102.0 million gain from selling the ELEVIDYS Priority Review Voucher and lower operating expenses. First-half net loss worsened by $204.2 million because of a $387.3 million non-cash loss on extinguishment of debt.
- In March 2023, Sarepta exchanged $313.5 million principal amount of 2024 Notes for approximately 4.5 million common shares, reducing debt carrying value by approximately $308.8 million versus December 31, 2022. The transaction also generated $80.6 million from partial settlement of related capped calls.
- Research and development expense decreased 4% in Q2 but increased 9% for the first half. Q2 spending reflected lower prior-year manufacturing charges, partially offset by higher clinical, personnel, facility and launch-related costs.
- Selling, general and administrative expense decreased 23% in Q2, primarily because of lower stock-based compensation, but increased 1% for the first half as personnel and launch-related professional services increased.
- The Bedford, Massachusetts lease commenced in May 2023, adding a $76.5 million lease liability and a $72.0 million right-of-use asset.
Guidance, outlook, commentary and risks
Management expects to continue incurring significant operating losses at least through 2023. The filing does not provide quantitative revenue or earnings guidance. Management identified anticipated 2023 milestones including FDA discussions regarding SRP-9003, top-line results from Study 9001-301 in the fourth quarter, top-line results from Part B of Study 5051-201 in the second half, and potential expansion of the ELEVIDYS label.
ELEVIDYS commercialization is a major strategic development, but the company has no prior ELEVIDYS product sales in the reported periods and relies on third-party manufacturing. Manufacturing commitments totaled approximately $1.28 billion, including $489.6 million due during July–December 2023. A Thermo Fisher amendment removed a prior annual minimum purchase commitment but created potential payments of up to $60.0 million, subject to specified waivers.
Products are approved under the accelerated approval pathway and require confirmatory trials and other post-marketing commitments. Failure to verify clinical benefit, unexpected safety findings, manufacturing problems or adverse regulatory decisions could restrict or withdraw approvals. Key clinical and regulatory milestones remain uncertain.
Material risks include dependence on U.S. product sales and a concentrated customer base, reimbursement and pricing pressure, competition, reliance on contract manufacturers and distributors, supply constraints, clinical-trial and enrollment risks, intellectual-property disputes, and the need for future financing. The company may owe up to $3.2 billion of contingent development, regulatory, commercial and royalty-related milestone payments under license and collaboration agreements.
Regenxbio and the Trustees of the University of Pennsylvania have asserted two patent infringement lawsuits involving AAV manufacturing technology and ELEVIDYS; a trial in the first case is scheduled for January 2024. Sarepta is also involved in patent litigation with Nippon Shinyaku, with a U.S. trial scheduled for May 2024 and separate proceedings in Japan. The filing states that no material litigation accrual or estimable material loss range was recorded as of June 30, 2023.
Most important facts for investors to verify
- ELEVIDYS launch timing, demand, reimbursement, manufacturing capacity and actual revenue contribution following the June 2023 approval.
- Results and regulatory implications of Study 9001-301, Study 5051-201 Part B and required confirmatory studies for all accelerated-approved products.
- Cash burn and runway relative to the 2024 and 2027 debt maturities, manufacturing commitments and potential milestone obligations.
- Progress and potential exposure in the Regenxbio/U-Penn and Nippon Shinyaku patent litigation.
- Whether ELEVIDYS displaces PMO product sales and creates excess or obsolete inventory.
- Customer concentration, product gross margins, payer coverage and the $114.0 million reserve for product discounts and allowances.
- Potential future dilution from approximately 12.1 million outstanding stock-award shares, convertible notes and possible equity financing.